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WehavedevelopedamicroencapsulationprocedurefortheentrapmentandmanipulationofIB3-1cysticﬁbrosiscells.Theapplied
methodisbasedongenerationofmonodispersedropletsbyavibrationalnozzle.Diﬀerentexperimentalparameterswereanalyzed,
including frequency and amplitude of vibration, polymer pumping rate and distance between the nozzle and the gelling bath. We
have found that the microencapsulation procedure does not alter the viability of the encapsulated IB3-1 cells. The encapsulated
IB3-1 cells were characterized in term of secretomic proﬁle, analyzing the culture medium by Bio-Plex strategy. The experiments
demonstrated that most of the analyzed proteins, were secreted both by the free and encapsulated cells, even if in a diﬀerent extent.
In order to determine the biotechnological applications of this procedure, we determined whether encapsulated IB3-1 cells could
be induced to pro-inﬂammatory responses, after treatment with TNF-α. In this experimental set-up, encapsulated and free IB3-1
cells were treated with TNF-α, thereafter the culture media from both cell populations were collected. As expected, TNF-α induced
a sharp increase in the secretion of interleukins, chemokines and growth factors. Of great interest was the evidence that induction
of interleukin-6 and interleukin-8 occurs also by encapsulated IB3-1 cells.
1.Introduction
Cystic ﬁbrosis (CF) is an autosomal recessive disorder caused
by mutations of the CF transmembrane conductance regula-
tor (CFTR) gene, which encodes a transmembrane protein
present on a variety of cell types and organelles [1]. The
most common mutation of the CFTR gene is a 3-base-pair
deletionresultinginthedeletionofphenylalanineatposition
508, known as the F508del CFTR mutation [1]. While CF is
classicallycharacterized by the presence of pancreatic insuﬃ-
ciencyandrecurrentlunginfectionsininfants,awideclinical
spectrum has been identiﬁed in adults [2, 3]. Chronic bacte-
rial infection of the airways, thickened airway mucous, and
bronchiectasis characterizes the CF lung [4]. The excess of
mucusislargelycausedbytheinﬂuxofneutrophils,attracted
to the site by the increased expression of chemokines such as
interleukin-6 (IL-6) [5] and interleukin-8 (IL-8) [5, 6], by
bacterial products and inﬂammatory cytokines.
For instance, IL-8, produced by macrophages, epithelial
cells, and ﬁbroblasts, is a potent chemokine and activator
for human neutrophils and it is considered to be an
important proinﬂammatory cytokine in the pathogenesis
of CF [2, 6–8]. IL-8 is induced transcriptionally by a wide
variety of stimuli including tumor necrosis factor-alpha
(TNF-α), hyperosmotic shock, and bacterial products such
as lipopolysaccharides [9].
In order to possibly study in detail the mechanism(s) of
activation of IL-8 in CF, there has been recently proposed
the IB3-1 cell system [10]. IB3-1 is a bronchial epithelial
cell line, derived from a CF patient with a CFTR genotype
of F508del/W1282X, therefore carrying the associated cystic
ﬁbrosis mutation [10–12]. This cell line can be induced
to high expression of proinﬂammatory proteins, following
infection with Pseudomonas aeruginosa or by treatment with
TNF-α. In both cases, 24-hour treatment with TNF-α is
usually suﬃcient to induce in IB3-1 cells a deep alteration of2 Journal of Biomedicine and Biotechnology
mRNAexpressionandproteinsecretionproﬁlewithatypical
increase of IL-6 and IL-8 mRNA and IL-6/IL-8 release [11].
Taking into consideration what stated above, it would
be of great interest to develop a speciﬁc system to possibly
study the mechanism of bacterial activation of IB3-1 cells as
well as the eﬀect of the secreted chemokines on target cell
populations, in coculture experiments. For instance, IB3-1
cells could be cocultured with Pseudomonas aeruginosa or
polymorphonuclear cells (PMN), the major phagocytic cells
of blood and also with other inﬂammatory cells such as
basophils, eosinophils, and T-cells [13, 14].
The coculture experiments could be performed in the
presence/absence of a semipermeable membrane embedding
the IB3-1 cells, representing a physical barrier to cell/cell
interactions but allowing the cross-talking among the diﬀer-
ent cells mediated by soluble factors.
In this respect, polysaccharidic-based microbeads rep-
resent one of the most intensively studied system to
immunoisolate cells or cell clusters, because of the spherical
shape and the small size that oﬀer an optimal surface to
volume ratio and an optimal diﬀusion capacity [15, 16].
The technology of cell microencapsulation is based
on the immobilization of living cells within a polymer
matrix, often alginate, that constitutes a semipermeable
membrane [15, 17]. The encapsulated cells are protected
against immune cell- and antibody-mediated actions and
have the potential to secrete active substances, generally with
am o l e c u l a rw e i g h t≤90kDa [15, 17].
These “living” delivery systems have been proposed
for controlled and continuous expression of a number
of compounds including hormones, growth factors, and
biological response modiﬁers.
The aim of the research work, here reported, is to deter-
mine whether IB3-1 cells can be conveniently encapsulated
in polymeric microbeads maintaining long-term in vitro
viability as well as their secretomic proﬁle when cultured in
standard conditions or after stimulation with TNF-α.
Summarizing, the current paper describes the following:
(a) the encapsulation of IB3-1 cells in alginate microbeads
following a microencapsulation procedure developed in our
laboratory that is based on the generation of monodisperse
droplets by an air-driven droplet generator for cell encap-
sulation; (b) the characterization of alginate microbeads
produced, with diﬀerent experimental parameters, including
atomizing air, polymer pumping rate, and distance between
the nozzle and the gelling bath; (c) the determination of
viability of the encapsulated IB3-1 cells, and ﬁnally (d) the
characterization of the encapsulated IB3-1 cells, in terms of
secretomic proﬁle, analyzing the culture medium by Bio-
Plex strategy [18–20]. The analyzed factors include members
of the interleukin family, chemokines, growth factors and
soluble forms of adhesion molecules.
2.MaterialsandMethods
2.1. Cell Cultures. IB3-1 cells were obtained from LGC
Promochem (Teddington, Middlesex, UK). Cells were grown
in LHC-8 basal medium (Bioﬂuids, Rockville, MD, USA),
supplemented with 5% FBS in the absence of gentamycin.
All culture ﬂasks and plates were coated with a solution
containing 35mg/mL bovine collagen (Becton-Dickinson
Italia, Milan, Italy), 1mg/mL bovine serum albumin (Sigma,
St. Louis, MO, USA), and 1mg/mL human ﬁbronectin
(Becton-Dickinson) [10].
2.2. Encapsulation of IB3-1 Cells. Monodisperse alginate
beads containing IB3-1 cells were prepared using an air-
driven droplet generator for cell encapsulation. Before
encapsulation, conﬂuent monolayers of IB3-1 were scraped
oﬀ by 0.05% trypsin/EDTA (Gibco, Grandisland, NY, USA)
(2min), washed with PBS, counted by hemocytometric
analysis, and assayed for viability by double staining with
propidium iodide (PI) and Calcein-AM (Sigma), following
the manufacturer’s indications. Brieﬂy, IB3-1 cells were
suspended in a 1.5% (w/v) aqueous solution of highly
puriﬁed sodium alginate (Inotech, Dottikon, Switzerland)
at a concentration of 8–12 × 106 cells/ml. The resulting cell
suspension was continuously aspirated by a syringe pump
and extruded through the air-driven droplet generator,
under sterile conditions. The generated microdroplets were
harderned by an ionotropic gelling process into a 1.2% (w/v)
barium chloride solution that resulted in the production
of barium alginate microbeads. After 3-minute incubation
into the gelling bath, the microbeads were washed twice
with saline and placed in LHC-8 basal medium (Bioﬂuids),
supplemented with 5% FBS at 37
◦C in an humidiﬁed
atmosphere of 5% CO2.
2.3. Dimensional and Morphological Characterization of
Alginate Microbeads. The morphology of barium alginate
microbeads was evaluated by optical microscopy and stere-
omicroscopy (Nikon microscopes, Tokyo, Japan). Microbead
size was determined by photomicrograph analyses
(Eclipsenet version 1.16.5; Laboratory AU5c Imaging s.r.o.
for Nikon B.V.). Samples of 200–400 beads were considered.
2.4. Viability Determination of Encapsulated IB3-1 Cells.
After encapsulation and after diﬀerent lengths of time, the
viability of IB3-1 cells was analyzed by double staining
with propidium iodide (PI) and Calcein-AM, following
manufacturer’s instructions. For the propidium iodide (PI)
and Calcein-AM analysis, cells were visualized under a
ﬂuorescence microscope (Nikon, Optiphot-2, Nikon Corpo-
ration, Japan). Viable cells were stained in green while the
dead ones were stained in red.
2.5. Experimental Design and Statistical Analysis. To study
the eﬀect and the inﬂuence of diﬀerent experimental
parameters on the size and size distribution of alginate
microbeads, a randomized central compositive face (CCF)-
centered design (CCF) consisting of 17 runs was used. The
experimental design and the evaluation of the experiments
were performed by the PC software MODDE 8.0 (Umetrics
AB, Sweden), followed by multiple linear regression (MLR)
algorithms. The following experimental parameters (“fac-
tors”) were considered: the atomizing air ﬂow (“air”), the
alginate pumping rate (“pump”), and the distance betweenJournal of Biomedicine and Biotechnology 3
the nozzle of air-driven droplet generator and the surface of
the gelling bath (“height”).
2.6. Treatment of IB3-1 with TNF-α. Treatment of monolay-
ers: IB3-1 cells were seeded at the initial concentration of
30,000cells/cm2 and the cell number/ml determined after 3
daysofculture.Cellnumber/mlwasdeterminedaftertrypsin
treatment by using a model ZBI Coulter Counter (Coulter
Electronics, Hialeah, FL, USA). Treatment of monolayers
with 80ng/mL TNF-α (PeProTech EC, London, UK) was
performed on 70% conﬂuent cells for 24 hours. Treatment of
encapsulated cells: equal quantity (20 × 106 cells) of free and
encapsulated cells (derived from the same ﬂask, previously
cultured for 3 days and successively detached by trypsin) was
treated with 80ng/mL TNF-α for 24 hours.
2.7. Cytokine Proﬁles. Cytokines in tissue culture super-
natants released from the cells under analysis were measured
by Bio-Plex cytokine assay (Bio-Rad Laboratories, Hercules,
CA) [21] as described by the manufacturer. The Bio-Plex
cytokine assay is designed for the multiplexed quantitative
measurement of multiple cytokines in a single well using as
little as 50μL of sample. In our experiments, the premixed
multiplex beads of the Bio-Plex human cytokine 7-plex
which included seven cytokines IL-1rα, IL-6, IL-8, G-CSF,
MCP-1 (MCAF), RANTES, and VEGF were used. 50μL
of cytokine standards or samples (supernatants recovered
from treated cells) were incubated with 50μL of anticytokine
conjugated beads in 96-well ﬁlter plates for 30min at
room temperature with shaking. Plates were then washed
by vacuum ﬁltration three times with 100μL of Bio-Plex
wash buﬀer, 25μL of diluted detection antibody were added,
and plates were incubated for 30min at room temperature
with shaking. After three ﬁlter washes, 50μL of streptavidin-
phycoerythrin were added, and the plates were incubated
for 10min at room temperature with shaking. Finally,
plates were washed by vacuum ﬁltration three times, beads
were suspended in Bio-Plex assay buﬀer, and samples were
analyzedonaBio-Rad96-wellplatereaderusingtheBio-Plex
Suspension Array System and Bio-Plex Manager software
(Bio-Rad Laboratories).
2.8. Quantiﬁcation of IL-8 and IL-6 Transcripts. Total RNA
was isolated (High Pure RNA isolation kit, Roche Applied
Science, Monza, Italy) and retro-transcribed (Promega Cor-
poration,Madison,USA),andtheresultingcDNAwasquan-
tiﬁed by relative quantitative real-time PCR. The sequences
of the oligonucleotides used for ampliﬁcation of IL-8 mRNA
were as follows: 5 -GTG CAG TTT TGC CAA GGA GT-3 
(forward) and 5 -TTA TGA ATT CTC AGC CCT CTT CAA
AAA CTT CTC-3  (reverse); for IL-6 mRNA: 5 -AGG AGA
CTT GCC TGG TGA AA-3  (forward) and 5 -CAG GGG
TGG TTA TTG CAT CT-3  (reverse); for GAPDH mRNA:
5 -AAGGTCGGAGTCAACGGATTT-3  (forward)and5 -
ACT GTG GTC ATG AGT CCT TCC A-3  (reverse).ForReal-
Time (RT) PCR, 0.5μL of cDNA were used for each Sybr
GreenRT-PCRreactiontoquantifytherelativetissueexpres-
sion of IL-8 and IL-6 transcripts. Each 25μLo ft o t a lr e a c t i o n
volume contained 0.5μL of cDNA, 10pmol of primers,
1 × iQ SYBR Green Supermix (Bio-Rad Laboratories). Real-
time PCR reactions were performed for a total of 40 cycles
(denaturation, 95
◦C for 10s; annealing, 68
◦C for 30s for IL-
8, 65
◦C for 30s for IL-6; elongation, 72
◦C for 60s) using an
iCycler IQ (Bio-Rad Laboratories). The relative proportions
of each template ampliﬁed were determined based on the
threshold cycle (Ct) value for each PCR reaction. The ΔΔCt
method was used to compare gene expression data. Each
samplewasquantiﬁedinduplicatefromatleasttwoindepen-
dent experiments. Mean±S.D. values were determined for
each fold diﬀerence. Ampliﬁcation of human GAPDH cDNA
served as internal standard (housekeeping gene). Duplicate
negative controls (no template cDNA) were also run with
every experimental plate to assess speciﬁcity and indicate
potential contamination.
2.9. Data Analysis and Statistics. Statistical analysis was
performed by one-way analysis of variance followed by the
Student’s t-test. A P value <.05 was considered statistically
signiﬁcant.
3. Results
3.1. Release of Proinﬂammatory Proteins by IB3-1 Cells
Exposed to TNF-α: a Bio-Plex Analysis. IB3-1 cystic ﬁbrosis
cell monolayers (see Figure 1(a)) were treated, after 3 days
of cell culture, for 24 hours in the presence of 80ng/mL
of TNF-α; thereafter, the conditioned media, from treated
and control cell populations, were analyzed for presence of
proinﬂammatory cytokines by Bio-Plex mediated analysis.
Before each induction experiment, IB3-1 cell monolayers
were assayed by “live/dead cells” test; in all cases the deter-
mined viability was ≥90%, as indicated by the ﬂuorescence
photomicrographs reported in the insets of Figure 1(a).
The Bio-Plex 200 multiplex suspension array repre-
sents, in fact, an assay system, employing Luminex xMAP-
technology, for the simultaneous detection and quantitation
of multiple bioanalytes (proteins, peptides, DNA and RNA)
in a single microplate, requiring only very small sample
volumes.
A number of proteins were considered in the analysis
of IB3-1 medium, namely, IL-1rα,G - C S F ,M C P - 1 ,I L - 6 ,
IL-8, RANTES, and VEGF. The obtained data, reported in
Figures 1(b) and 1(c), indicate that, apart from RANTES and
VEGF (which values are not statistically diﬀerent in control
versus treated cells), all other proteins are diﬀerentially
expressed and released in untreated IB3-1 cells and after
TNF-αtreatment.Inparticular,IL-6andIL-8werepresentat
high concentrations, in the medium of TNF-α treated cells,
reaching values of 5.71 and 5.84ng/mL, respectively.
3.2. Encapsulation of IB3-1 Cells in Alginate Microbeads. IB3-
1 cells were embedded into alginate microbeads by an air-
driven droplet generator for cell encapsulation (see scheme
in Figure 2) .T h ee n c a p s u l a t i o np r o c e d u r ew a sr e l a t i v e l y
simple and consisted of a limited number of steps. In
order to achieve complete biocompatibility, essential for4 Journal of Biomedicine and Biotechnology
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Figure 1: Morphology (a) and viability (insert) of IB3-1 cell
monolayers, as determined by bright ﬁeld and ﬂuorescence pho-
tomicrographs. Fluorescence photomicrographs were taken after
doublestainingwithCalcein-AMandpropidiumbromide.Analysis
of the release of proinﬂammatory cytokines by IB3-1 cells, as deter-
minatedbyBio-Plexanalysis(b,c).Theindicatedproteinswereana-
lyzedintheIB3-1cellculturemedium,namely,IL-1rα(Interleukin-
1 receptor alpha), G-CSF (Granulocyte-colony stimulating factor),
MCP-1 (Monocyte chemotactic protein-1), IL-6 (Interleukin 6),
IL-8 (Interleukin 8), RANTES (Regulated upon activation, normal
T cell expressed and secreted), and VEGF (Vascular endothelial
growth factor). Data are referred to control untreated cells (open
bars) and to cells treated for 24 hours with TNF-α (80ng/mL)
(closed bars). Data represent the average ± SD (N = 3).
mammalian cells, the entire procedure was conducted at
room temperature, under physiologic pH and tonicity using
a pyrogen-free alginate [16, 17]. The hardening of the
generated alginate microdroplets was accomplished by an
ionic gelation procedure, by barium chloride. The resulting
barium alginate microbeads were elastic and transparent,
thus facilitating the microscopic observation of cell mor-
phology and viability, during the in vitro studies, as evident
by the brightﬁeld and darkﬁeld stereophotomicrographs
shown in Figure 3.
For the screening and optimization of the experimental
parameters, a “design of the experiments” (DoE) was
performed, after design by MODDE software. The DoE
reduces the number of experiments and provides statistical
information about the eﬀects of diﬀerent variables and their
possible interactions.
A centralcomposite design (oneof themost used designs
in pharmaceuticals and biological studies) was applied to
the optimization of alginate microbeads. This experimental
design required 17 experiments (2k +2 k +3 ,w h e r ek is
the number of variables) including three center points in
order to have an estimation of the experimental error. The
high and low values of each variable were deﬁned based on
preliminary experiments.
The factors/responses and the general results of DoE
analysis are reported in Table 1 and Figures 4 and 5,
respectively. In particular, in Figure 4 are shown the contour
plots, while the response surface plots of the investigated
factors are given in Figure 5; the inﬂuence of factors on “size”
is given in (a)–(c) and “SD” in (d)–(f).
The main observation was that a change in “air” value
from a low to a high level (12 to 20 bar) results in a sharp
decrease of the microbead “size” while the “SD” response
presents a biphasic trend showing a minimum at the central
value for both “air” and “pump”. The “height” and “pump”
parameters exert an inﬂuence at their high and low levels
causingtheincreaseofboththeresponses.Afterinvestigation
of the factor inﬂuence, the validity and the signiﬁcance of
the model was estimated by analysis of variance (ANOVA).
All the data obtained ﬁt well the model determining a
good reproducibility of the studied model. We get a large
regression coeﬃcient R2 that is a necessary condition for a
validity model with a signiﬁcant power of prediction of the
model Q2 (data not shown).
3.3. Viability of Encapsulated IB3-1 Cells. Ac r u c i a li s s u e
that should be always investigated in the case of embed-
ding/seeding protocols for cell scaﬀolding concerns the eﬀect
of the encapsulation procedure on viability of cells. For this
purpose, the viability of encapsulated cells in alginate beads
was determined by the live/dead test. Beads were incubated
with Calcein-AM (a marker of living cells; ﬂuorescent signal
was monitored using 485nm excitation wavelength and
530nm emission wavelength) and with PI (a marker of cell
death; excitation, 535nm; emission, >610nm). The obser-
vation of the ﬂuorescent images recorded immediately after
the encapsulation procedure at the typical excitation wave-
lengths (Figure 6) indicated that the cells were highly viable
(>95%) after diﬀerent lengths of culture time (up to 7 days).
3.4. Increase of Accumulation of IL-8 and IL-6 mRNAs Is
Clearly Detectable in Encapsulated IB3-1 Cells Treated with
TNF-α. FreeandencapsulatedIB3-1cysticﬁbrosiscellswere
treated for 24 hours in the presence of 80ng/mL of TNF-α.
After this treatment, microcapsules were separated from the
culture medium, washed, fused and entrapped cells isolated,
washed, and ﬁnally lysed for RNA isolation. RT-PCR was
performed using primers amplifying IL-8, IL-6, and GAPDH
RNA sequences. The results obtained are reported in Fig-
ure 7(a), which clearly indicates that encapsulation has only
minor eﬀects on IL-8 mRNA accumulation. Consistently, inJournal of Biomedicine and Biotechnology 5
IB3-1 monolayer
in LHC-8 medium
Syringe pump
rate 75-125 μl/min
Sodium alginate inlet
at 10◦C
Atomizing air inlet
inert gas at 25◦C
Sodium alginate
microdroplets
Gelling bath
BaCl2
Barium alginate
microbeads
Free IB3-1 cells
monolayer
IB3-1 cells encapsulated in
barium alginate microbeads
Sodium alginate
+
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TNF-α IL-8 TNF-α IL-8
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Figure 2: General scheme of the encapsulation procedure for IB3-1 cells by monojet air-driven device. The lower part of the ﬁgure
summarizes the procedure for the in vitro experiments with free (right) and encapsulated IB3-1cells (left) treated with TNF-α.
TNF-α-treated cells (closed bars) the levels of IL-6 and IL-
8 mRNA sequences are higher than those usually found in
TNF-α untreated IB3-1 cells (open bars). Moreover, TNF-α
inductionofIL-6(Figure7(a),leftsideofthepanel)andIL-8
(Figure7(a),rightsideofthepanel)geneexpressionisclearly
evident,bothinfree(control)andencapsulated(CAPS)IB3-
1 cells, strongly indicating that (a) TNF-α transfer within
the alginate microbeads takes place with high eﬃciency and
(b) its expected eﬀects on gene expression is detectable,
mimicking the well-known eﬀect of TNF-α on free IB3-1
cells. In order to determine whether the increases of IL-6
and IL-8 mRNA direct synthesis of the respective proteins
and their secretion outside the alginate microbeads, Bio-Plex
analysis on the medium was performed.
3.5. Increased Release of IL-6 and IL-8 outside the Micro-
capsules Entrapping IB3-1 Cells Treated with TNF-α. Free
and encapsulated IB3-1 cystic ﬁbrosis cells were treated for
24 hours in the presence of 80ng/mL of TNF-α. After this
treatment, microcapsules were separated from the culture
medium, which was analyzed for content of IL-6 and IL-
8. Figure 7(b) shows that minor diﬀerences in the amounts
of secreted IL-6 and IL-8 protein levels are present when
mediums isolated from cultures of free (control) and encap-
sulated (CAPS) IB3-1 cells are compared. On the contrary,
when release by TNF-α-treated cells is compared to that of
c o n t r o lI B 3 - 1c e l l s( c o m p a r eb l a c kt ow h i t eh i s t o g r a m so f
Figure 7(b)), the levels of IL-6 and IL-8 increase signiﬁcantly
both in free (control) and in encapsulated (CAPS) IB3-1
cells. The TNF-α-mediated fold induction of IL-8 release
was found similar in free and encapsulated IB3-1 cells
(Figure 7(b), right side of the panel), while in the case of
IL-6, the fold increase was more evident in free IB3-1 cells
(Figure 7(b), left side of the panel). This observation was
reproducibly obtained in several experiments.
4. Discussion
The ﬁrst aim of the present paper was to verify if IB3-
1 cystic ﬁbrosis cells could be encapsulated in alginate
microbeads and to test if the immobilized cells could
be induced to express proinﬂammatory genes, after
treatment with TNF-α (see the scheme of the experiment
shown in Figure 2). In this respect, we demonstrated that6 Journal of Biomedicine and Biotechnology
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Figure 3: Bright ﬁeld (a,b) and dark ﬁeld (c) stereophotomi-
crographs of empty (a) and IB3-1 containing (b,c) alginate
microbeads. Microbeads were produced by the monojet air-driven
device. Alginate microbeads were prepared using the experimental
parameters reported in Table 1 (batch #15a, b, c).
IB3-1 cells can be eﬃciently encapsulated in microbeads
that posses a number of speciﬁc requisites, such as spherical
shape, very narrow size distribution, good mechanical
stability, and biocompatibility, assuring cell viability and
functions. These ﬁndings are in agreement with several
observations indicating that this strategy is a useful tool
to entrap functionally active cells, as published by several
research groups [22–24]. For instance, human mesenchymal
progenitor cells were immobilized in alginate microbeads by
Endres et al. [23] and by Penolazzi et al. [24], demonstrating
that after encapsulation, they maintain the ability to undergo
chondrogenic diﬀerentiation.
The second aim of our experimental strategy was to
verify whether TNF-α eﬃciently induces gene expression
alterations in the encapsulated IB3-1 cells. The results
obtained by RT-PCR analysis of RNA ﬁrmly demonstrate
that (a) encapsulation induces only a limited increase of
the basal IL-6 and IL-8 mRNA content, whereas (b) TNF-
α stimulates a sharp increase of content of IL-6 and
IL-8 mRNAs in both free and encapsulated IB3-1 cells.
This latter result suggests that TNF-α eﬃciently diﬀuses
through the alginate microbeads matrix. Therefore, alginate
microbeads could be suitably employed in experiments, in
which the target cells are grown in a physically separated,
immunoisolated environment, being however accessible to
externallyaddedsolubleproteinspossiblycausingalterations
of gene expression.
However, in order to propose the described system as an
experimental model to study cystic ﬁbrosis, further experi-
ments are required to control several unmet issues, including
the fact that the encapsulated cells are nonadherent, are
not polarized and are unable to bind to bacteria (such
as Pseudomonas aeruginosa) and immune cells inducing
responses verydiﬀerentfromthoseofsoluble mediators (i.e.,
TNF-α). These are several parameters playing important
rolesinmodiﬁcationofgeneexpressionincysticﬁbrosiscells
[25–27].Inthisrespect,weliketounderlinethatthealginate-
based encapsulation strategy can be further improved. For
instance, in our laboratories, experiments in progress are
aimed to the production of composites multifunctional
microbeads simultaneously containing (a) living cells and
(b) an extracellular matrix component, namely, a particulate
ECM, that is able to modulate cell adhesion, migration,
and polarization. In addition, coencapsulation of epithelial
cells and eﬀector cells is technically feasible and might be
explored.
Finally, the third aim of our experimental strategy
was to verify whether TNF-α treatment leads to increased
production and release of IL-6 and IL-8, conﬁrming the
permeability of the alginate microbeads membrane to these
proteins. The results obtained ﬁrmly demonstrate that IL-6
and IL-8 release outside the microbeads increases in IB3-1
encapsulated cell cultures strongly suggesting that the algi-
nate microbeads membrane is permeable to these proteins.
However, while the TNF-α-mediated fold induction of IL-8
release was found similar in free and encapsulated IB3-1
cells, we reproducibly noted that in the case of IL-6 the fold
increase was more evident in free cells than that in encapsu-
lated IB3-1 cells. This might be due to a diﬀerential intracel-
lular synthesis of IL-6 and IL-8 mRNAs or to a diﬀerential
permeability of the capsule membranes to IL-6 and IL-8, or
both. While additional experiments are required to explain
this phenomenon, the possibility that the chemical compo-
sition of the microcapsule inﬂuences drug release charac-
teristics has been recently proposed by Jaya et al. and might
be used to develop microbeads allowing selective releases
[28].Journal of Biomedicine and Biotechnology 7
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Figure 4: DoE analysis for the production of alginate microbeads containing IB3-1 cells. Contour plots of the responses: “size” (a)–(c) and
“SD” (d)–(f). The following interactions were reported: “height versus air” (a,d); “pump versus air” (b,e); and “pump versus height” (c,f).8 Journal of Biomedicine and Biotechnology
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Figure 5: DoE analysis for the production of alginate microbeads containing IB3-1 cells. Response surface plots of the responses: “size”
(a)–(c) and “SD” (d)–(f). The following interactions were reported: “air versus pump” (a,d); “air versus height” (b,e); and “pump versus
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(c) (d)
Figure 6: Optical (a,c) and ﬂuorescence (b,d) photomicrographs of alginate microbeads containing IB3-1 cells after 1 (a,b) and 7 days (c,d)
of cell culture. Fluorescence photomicrographs were taken after double staining with Calcein-AM and propidium bromide.
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Figure 7: Analysis of the mRNA levels (a) and release (b) of interleukins 6 and 8 (IL-6, IL-8) by IB3-1 cells. Data are referred to control free
cells growing as monolayer (control) and cells encapsulated in alginate microbeads (CAPS). Both free and encapsulated cells were cultured
for 24 hours, in the absence (open bars) or in the presence of TNF-α (80ng/mL) (closed bars). Data represent the average ±SD (N = 3).
In this respect, the use of cell-based drug delivery
has been proposed as a very promising application of
encapsulation of cells relevant for production of therapeutic
proteins [29–33]. For instance, erythropoietin-secreting cells
immobilizedinmicrocapsuleshavebeendescribedbyMurua
et al. [29]. The applications in biomedicine of this strategy
are very high, in consideration of the importance of erythro-
poietin for several biological functions, and the pathological
conditions due to its disregulation. Similarly, continuous
production of IL-12 by microencapsulated engineered cells10 Journal of Biomedicine and Biotechnology
Table 1: Experimental design matrix and results of the DoE (design of experiments) approach for alginate microbeads.
Factors Responses
Batch # Atomizing air (bar)
Distance between the
nozzle and the gelling
bath (cm)
Polymer pumping rate
Pump (μm/mL) Mean diameter (μm) Standard deviation
(±μm)
“air” “height” “pump” “size” “SD”
#1 12.0 2.2 75.0 1350.5 63.2
#2 20.0 2.2 75.0 983.1 68.4
#3 12.0 3.0 75.0 1234.1 389.5
#4 20.0 3.0 75.0 917.5 60.5
#5 12.0 2.2 125.0 1177.5 296.5
#6 20.0 2.2 125.0 716.7 99.2
#7 12.0 3.0 125.0 1161.1 83.6
#8 20.0 3.0 125.0 724.8 106.7
#9 12.0 2.6 100.0 1293.6 47.6
#10 20.0 2.6 100.0 835.4 322.3
#11 16.0 2.2 100.0 970.5 54.8
#12 16.0 3.0 100.0 851.6 36.3
#13 16.0 2.6 75.0 920.6 47.2
#14 16.0 2.6 125.0 974.9 58.1
#15a 16.0 2.6 100.0 920.8 43.1
#15b 16.0 2.6 100.0 920.8 43.1
#15c 16.0 2.6 100.0 920.8 43.1
modiﬁed with murine interleukine-12 (mIL-12) gene has
been reported by Zheng et al. [34]. The microencapsulated
cells have a signiﬁcant therapeutic eﬀect on experimental
colon tumors by activating antitumor immune responses
in vivo. These and similar papers support the concept that
microencapsulated and genetically engineered cells may be
an extremely versatile tool for cellular therapy [35].
In our case, we demonstrate that microencapsulated cells
can be induced to produce IL-8 in the presence of high
levels of TNF-α. This result allows to hypothesize that the
experimental strategy outlined allows the development of a
“cell-based microparticle sensor” releasing speciﬁc proteins
(selective release can be improved by changing the chemical
composition of the microcapsules) [36] upon stimulation.
This might be of great interest in biomedicine [35].
Bioencapsulation has been indeed shown to be eﬃcacious
in mimicking the cell’s natural environment and thereby
improvestheeﬃciencyofproductionofdiﬀerentmetabolites
and therapeutic agents, while protecting the cells from larger
proteins (e.g., antibodies) and immune cells [29, 32, 35].
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